% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Radujkovic:128648,
      author       = {A. Radujkovic and L. Kordelas and J. Krzykalla$^*$ and D.
                      W. Beelen and A. Benner$^*$ and N. Lehners$^*$ and K.
                      Schmidt and P. Dreger and T. Luft},
      title        = {{P}retransplant {V}itamin {D} {D}eficiency {I}s
                      {A}ssociated {W}ith {H}igher {R}elapse {R}ates in {P}atients
                      {A}llografted for {M}yeloid {M}alignancies.},
      journal      = {Journal of clinical oncology},
      volume       = {35},
      number       = {27},
      issn         = {1527-7755},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2017-04664},
      pages        = {3143 - 3152},
      year         = {2017},
      abstract     = {Purpose Vitamin D (VitD) deficiency is common in patients
                      with hematologic malignancies undergoing allogeneic
                      transplantation (alloSCT), but its prognostic relevance is
                      unclear. Patients and Methods The impact of pretransplant
                      VitD status on overall survival, relapse mortality, and
                      nonrelapse mortality was investigated retrospectively in a
                      cohort of 492 patients undergoing alloSCT at our center from
                      2002 to 2013. VitD deficiency was defined as a serum level
                      of 25-hydroxyvitamin D3 < 20 ng/mL (equivalent to < 50 nM)
                      before alloSCT and was assessed using accredited laboratory
                      methods and a standard chemiluminescent immunoassay. Results
                      were validated in an independent cohort of 398 patients
                      diagnosed with myeloid malignancies. Results A total of 396
                      $(80\%)$ and 348 $(87\%)$ patients had VitD deficiency
                      before alloSCT in the training and validation cohort,
                      respectively. In the training cohort, VitD deficiency was
                      significantly associated with inferior overall survival
                      (hazard ratio [HR], 1.78; P = .007) in multivariable
                      analysis. This was due to a higher risk of relapse (HR,
                      1.96; P = .006) rather than nonrelapse mortality. A
                      significant association of pretransplant VitD deficiency
                      with higher relapse rates was observed only in patients
                      diagnosed with myeloid (HR, 2.55; P = .014) but not with
                      lymphatic diseases (HR, 1.60; P = .147). A similar impact of
                      pretransplant VitD deficiency on relapse risk in myeloid
                      diseases was also observed in an independent patient cohort
                      (HR, 2.60; P = .017). Validation of the effect of VitD
                      deficiency on relapse in patients with myeloid malignancies
                      was successful. Conclusion Pretransplant VitD deficiency was
                      associated with a higher risk of relapse in patients
                      allografted for myeloid malignancies. Prospective studies on
                      VitD status and correction of VitD deficiency in the setting
                      of alloSCT are highly warranted.},
      cin          = {C060 / G170},
      ddc          = {050},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)G170-20160331},
      pnm          = {319H - Addenda (POF3-319H)},
      pid          = {G:(DE-HGF)POF3-319H},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28771378},
      doi          = {10.1200/JCO.2017.73.0085},
      url          = {https://inrepo02.dkfz.de/record/128648},
}